News|Articles|January 28, 2026
Enhanced Paveway™ PLUS Selects Expression Organisms Based on Titer Plus Quality
Author(s)Fujifilm
Discover the future of microbial expression with a platform that optimizes strain selection, expression systems, and purification methods, providing actionable insights in just eleven weeks.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5